News

Latest news

30th November 2023

Acticor Biotech completes a capital increase for a total gross amount of approximately 2.6 million euros, via the issuance of 850,360 shares

Read more
29th November 2023

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

Read more
19th October 2023

Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission

Read more
19th October 2023

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

Read more
20th September 2023

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

Read more
19th September 2023

Sequana Medical announces H1 2023 results and provides business update

Read more
19th September 2023

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

Read more
19th September 2023

Ann Meulemans and AbolerIS Pharma is featured in De Tijd newspaper

Read more
5th September 2023

ACTIMIS post-hoc results on imaging stroke data using Artificial Intelligence reinforces glenzocimab mode of action in stroke patients

Read more